Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Fibrogen Inc (FGEN) USD0.01

Sell:$41.77 Buy:$41.83 Change: $0.13 (0.31%)
NASDAQ:0.51%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$41.77
Buy:$41.83
Change: $0.13 (0.31%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$41.77
Buy:$41.83
Change: $0.13 (0.31%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

Contact details

Address:
409 Illinois St
SAN FRANCISCO
94158-2509
United States
Telephone:
+1 (415) 9781200
Website:
www.fibrogen.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
FGEN
ISIN:
US31572Q8087
Market cap:
$3.71 billion
Shares in issue:
89.10 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Schoeneck
    Chairman of the Board
  • Enrique Conterno
    Chief Executive Officer, Director
  • Pat Cotroneo
    Chief Financial Officer
  • Christine Chung
    Senior Vice President, China Operations
  • Elias Kouchakji
    Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance
  • Thane Wettig
    Chief Commercial Officer
  • Kin-Hung Yu
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.